Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Safety|September 4, 2019
The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxicsDominique Levêque, Guillaume Becker
European Journal of Nuclear Medicine and Molecular Imaging|August 13, 2021
Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studiesFabien Chauveau, Guillaume Becker, Hervé Boutin
Clinical Pharmacokinetics|March 1, 2020
Clinical Pharmacokinetics and Pharmacodynamics of DasatinibDominique Levêque, Guillaume Becker, Karin Bilger, et al.
Molecules (Basel, Switzerland)|May 20, 2020
The Rise of Synaptic Density PET ImagingGuillaume Becker, Sylvestre Dammicco, Mohamed Ali Bahri, et al.
Molecular Psychiatry|July 12, 2024
PET imaging of neuroinflammation: any credible alternatives to TSPO yet?Fabien Chauveau, Alexandra Winkeler, Sylvie Chalon, et al.
Journal of Medicinal Chemistry|April 24, 2014
Syntheses, radiolabelings, and in vitro evaluations of fluorinated PET radioligands of 5-HT6 serotoninergic receptorsJulie Colomb, Guillaume Becker, Sylvain Fieux, et al.
CNS Neuroscience & Therapeutics|July 22, 2014
A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's diseaseGuillaume Becker, Nathalie Streichenberger, Thierry Billard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 22, 2014
Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imagingGuillaume Becker, Julie Colomb, Véronique Sgambato-Faure, et al.
Pageof 5